MedTrace Logo

Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

NCT02049125 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2016-10-27

No results posted yet for this study

Summary

The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with cirrhosis and bacterial infection and to predict response to AKI treatment with albumin and albumin with terlipressin in patients with suspected hepatorenal syndrome.

Conditions

Sponsors & Collaborators

  • Federal University of Rio Grande do Sul

    collaborator OTHER

  • Federal University of Espirito Santo

    collaborator OTHER

  • Hospital de Base

    collaborator OTHER

  • University of Campinas, Brazil

    collaborator OTHER

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Alberto Q Farias, Associate professor · University of Sao Paulo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-12-31
Completion
2018-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02049125 on ClinicalTrials.gov